Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
For newly diagnosed CIDP, initiate treatment with either intravenous immunoglobulin (IVIg) or corticosteroids as first-line therapy, with plasma exchange reserved for patients who fail to respond to these initial treatments. 1
First-Line Treatment Options
The 2021 European Academy of Neurology/Peripheral Nerve Society guidelines provide strong recommendations for three evidence-based first-line therapies 1:
Intravenous Immunoglobulin (IVIg)
- IVIg is strongly recommended as initial treatment for typical CIDP and CIDP variants 1
- Should be considered as the preferred first-line treatment specifically for motor CIDP 1
- Effective for both induction and maintenance therapy 2
- Subcutaneous immunoglobulin is also recommended for maintenance treatment 1
Corticosteroids
- Corticosteroids are strongly recommended as initial treatment alongside IVIg 1
- Effective for both induction and maintenance phases 2
- Can be administered as daily oral therapy or pulse therapy 2
- Recommended for maintenance treatment 1
Plasma Exchange
- Strongly recommended only if IVIg and corticosteroids prove ineffective 1
- Effective as induction treatment 2
- Reserved as second-line therapy rather than initial approach 1
Treatment Algorithm
Initial Phase:
- Start with either IVIg or corticosteroids based on patient characteristics 1
- For motor-predominant CIDP, prioritize IVIg 1
- Monitor response to initial therapy 3
If Inadequate Response:
- Switch to the alternative first-line agent (IVIg ↔ corticosteroids) 1
- If both fail, escalate to plasma exchange 1
Maintenance Treatment Strategy
For patients responding to initial therapy:
- Continue with IVIg, subcutaneous immunoglobulin, or corticosteroids for maintenance 1
- If maintenance doses become excessively high, consider combination treatments or add immunosuppressant/immunomodulatory drugs 1
- This approach serves as a steroid-sparing strategy when needed 1
Second-Line and Escalation Therapies
When first-line treatments fail or require dose reduction 4:
- Immunosuppressants may be introduced as steroid-sparing agents 4
- Rituximab can be used in special cases 4
- Novel therapies under investigation include molecules targeting Fc receptors and complement inhibition 4, 5
Monitoring and Symptomatic Management
Pain Management:
- If neuropathic pain is present, prescribe drugs specifically for neuropathic pain and implement multidisciplinary pain management 1
- This addresses a common disabling symptom that requires specific attention beyond immunomodulatory therapy 3
Response Monitoring:
- Assess treatment response systematically 3
- Evaluate ongoing need for therapy at regular intervals 3
- Consider non-pharmacological interventions as adjunctive therapy 3
Critical Treatment Considerations
The heterogeneous disease course and lack of surrogate parameters to predict clinical deterioration make CIDP treatment challenging 4. Despite multiple established therapies, treatment remains difficult to optimize 3. The key is to initiate appropriate first-line therapy promptly, monitor response systematically, and escalate or modify treatment based on clinical response rather than waiting for complete treatment failure 1.
Common pitfall: Misdiagnosis is frequent in CIDP, leading to inappropriate therapy 6, 7. Ensure diagnostic criteria are met using the 2021 EFNS/PNS guidelines before initiating immunomodulatory treatment 7.